Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
DyNAbind GmbH logo — Accelerating Drug Discovery

DyNAbind GmbH

Accelerating Drug Discovery

Founded 2017 Germany Dresden, Germany 8 employees Seed Biopharma, Biotechnology

General Information

Company Name DyNAbind GmbH
Founded Year 2017
Location Germany Dresden, Germany
Founders / Decision Makers
Team member
Employees 8
Industries Biopharma, Biotechnology
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with DyNAbind GmbH. To contact DyNAbind GmbH, visit dynabind.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DyNAbind GmbH compare?

A PDF of DyNAbind GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DyNAbind GmbH soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DyNAbind GmbH

DyNAbind is a Germany-based startup that is revolutionizing drug discovery with its innovative DNA-Encoded Library platform. Founded in 2017, the company's slogan "Accelerating Drug Discovery" encapsulates its mission to provide fast, reliable, and high-quality medicinal chemistry starting points for various protein targets. The recent Seed Round investment at 08 May 2019 saw participation from notable investors including High-Tech Gründerfonds, TGFS - Technologiegründerfonds Sachsen, and TUDAG. DyNAbind's technology differentiates itself from traditional high-throughput screening methods by enabling simultaneous selection from hundreds of millions of molecules, offering superior signal-to-noise ratios, reduced false positive rates, and rapid hit validation. This approach significantly expedites the hit discovery process, delivering results in just a few weeks compared to over a year using conventional methodologies. The company prides itself on its customer focus, catering to diverse partners including big pharma, biotech, and academic groups. DyNAbind is poised to engage and collaborate with partners to tailor customized workflows and financial structures to meet specific discovery needs, showcasing a dynamic and customer-centric approach to its operations.

Business keywords: Drug Discovery, DNA-Encoded Libraries, Small Molecule Discovery, Fragment-Based Discovery, Medicinal Chemistry, Pharmaceutical Research, Biotechnology Innovation, High-Throughput Screening, Protein Targets, Innovative Technology, Biotech Partnership, Academic Collaborations

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 3
TGFS - Technologiegründerfonds Sachsen TUDAG
TGFS - Technologiegründerfonds Sachsen, TUDAG +1
08 May 2019

DyNAbind GmbH Alternatives & Competitors

View All Alternatives
DyNAbind GmbH vs
DELIVER Therapeutics, Inc.
DELIVER Therapeutics, Inc. United States

Applying high throughput screening technologies to deliver novel therapeutics

7 employees
Biopharma, Biotechnology
DyNAbind GmbH vs
Terray Therapeutics
Terray Therapeutics United States

Everything small molecule drug discovery should be.

Series B
142 employees
AI, Biopharma
DyNAbind GmbH vs
PhoreMost Ltd
PhoreMost Ltd United Kingdom

Drugging the Undruggable®

Series B
33 employees
Biopharma, Biotechnology
View all alternatives

FAQ About DyNAbind GmbH

Accelerating Drug Discovery
DyNAbind GmbH was founded in 2017.
DyNAbind GmbH is headquartered in Dresden, Germany.
DyNAbind GmbH operates in Biopharma and Biotechnology. Its work centres on Drug Discovery, DNA-Encoded Libraries, Small Molecule Discovery and Fragment-Based Discovery.
DyNAbind GmbH has approximately 8 employees.
DyNAbind GmbH has completed 1 funding round. The latest funding stage is Seed.
Top alternatives and competitors to DyNAbind GmbH include DELIVER Therapeutics, Inc., Terray Therapeutics, PhoreMost Ltd, synplogen, Protillion Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DyNAbind GmbH and DELIVER Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DyNAbind GmbH, https://bouncewatch.com/company/dynabind, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes